Acta Diabetologica

, Volume 55, Issue 10, pp 1059–1066 | Cite as

Real-world use of self-monitoring of blood glucose in people with type 2 diabetes: an urgent need for improvement

  • Maria Chiara RossiEmail author
  • Giuseppe Lucisano
  • Antonio Ceriello
  • Chiara Mazzucchelli
  • Nicoletta Musacchio
  • Alessandro Ozzello
  • Antonio Nicolucci
  • Paolo Di Bartolo
  • the AMD Annals-SMBG Study Group
Original Article



To assess use of self-monitoring of blood glucose (SMBG) in type 2 diabetes (T2DM) in the context of a continuous quality improvement initiative (AMD Annals).


14 quality-of-care indicators were developed, including frequency of SMBG, fasting blood glucose (FBG), and post-prandial glucose (PPG) levels, and hypoglycemia and hyperglycemia episodes. Clinical data and SMBG values downloaded from any glucose meter were obtained from electronic medical records. The most frequently used glucose-lowering treatment regimens were identified and the indicators were assessed separately by regimen.


Overall, 21 Italian centers and 13,331 patients (accounting for 35,657 HbA1c tests and 8.44 million SMBG values collected during 2014 and 2015) were included in the analysis; 11 therapeutic regimens were selected. Patients in regimens not including insulin performed 15–23 measurements per patient-month, those treated with basal insulin 32.1 tests/patient-month, and those treated with basal and short-acting insulin 53–58 tests/patient-month. In all treatment regimens, PPG measurements represented a minority of all tests; pre-breakfast measurements accounted for about 50% of all FBG values. Mean FBG levels exceeded 130 mg/dl in 49.3–88.3% of the cases in the different treatment regimens, while PPG levels were over 140 mg/dl in 46.7–81.0%. From 5.7 to 32.7%, patients in the different regimens had at least one episode of hypoglycemia (< 70 mg/dl), while from 3.7 to 47.7% had at least one episode of hyperglycemia (> 300 mg/dl).


SMBG is underutilized in patients with T2DM treated or not with insulin. In all treatment groups, PPG is seldom investigated. Poor metabolic control and rates of hyper- and hypoglycemia deserve consideration in all treatment groups.


Self-monitoring blood glucose Type 2 diabetes Quality of care Benchmarking Adherence 





American Diabetes Association


Associazione Medici Diabetologi


Basal insulin


Dipeptidyl peptidase-4 inhibitor


European Association for the Study of Diabetes


Electronic medical record


Fasting blood glucose


Glucagon-like peptide-1 receptor agonists


Glycated hemoglobin


International Diabetes Federation




Oral hypoglycemic agent


Post-prandial glucose


Standard deviation




Short-acting insulin


Self-monitoring blood glucose


Type 2 diabetes

95% CI

95% confidence interval



The study was promoted by the AMD scientific society through an unconditional Grant by Sanofi SpA, Milan, Italy. The authors thank the participating diabetes outpatient centers for their contribution. The authors acknowledge Sanofi—Italy for having supported this work. The sponsor did not participate in the design or conduct of this study; in the collection, management, analysis, or interpretation of data; in the writing of the manuscript; and in the preparation, review, approval, or decision to submit this manuscript for publication. AMD ANNALS-SMBG Study Group list of investigators: Nuzzi Annamaria—Alba, Canale (CN), Velussi Mario—Aurisina (TS), Spanu Francesca—Cagliari, Del Buono Andrea—Cellole (CE), Santantonio Graziano—Civitavecchia (RM), Magro Giampaolo—Cuneo, Garrapa Gabriella—Fano (PU), Antenucci Daniela—Lanciano (CH), Laudato Mario—Maddaloni (CE), Saitta Giovanni—Messina, Stroppiana Mauro—Nizza Monferrato (AT), D’Agati Francesco—Palermo, Anichini Roberto—Pescia (PT), Di Bartolo Paolo—Ravenna, Rastelli Emilio—Riccione (RN), Leotta Sergio—Roma, Felace Giuseppe—Spilimbergo (PN), Lalli Carlo—Spoleto (PG), Tonutti Laura—Udine.


The study was supported by a unconditional Grant from Sanofi SpA, Milan, Italy.

Compliance with ethical standards

Conflict of interest

The author(s) declare that they have no competing interests.

Statement of human and animal rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).

Statement of informed consent

Based on the study design and Italian regulations, the study protocol was approved by the local Ethics Committees and the signed informed consent was not required.

Supplementary material

592_2018_1186_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 17 KB)


  1. 1.
    Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:136413–136479 (Erratum in: Diabetes Care 2013;36:490) CrossRefGoogle Scholar
  2. 2.
    Ceriello A, Gallo M, Armentano V et al (2012) Personalizing treatment in type 2 diabetes: a self-monitoring of blood glucose inclusive innovative approach. Diabetes Technol Ther 14:373–378CrossRefPubMedGoogle Scholar
  3. 3.
    Ceriello A, Genovese S, Bosi E (2016) The evolving frontier of diabetes therapy: the renaissance of glycemology. Diabetes Res Clin Pract 118:168–171CrossRefPubMedGoogle Scholar
  4. 4.
    Ceriello A, Gallo M, Candido R et al (2014) Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmgenomics Pers Med 7:129–136PubMedPubMedCentralGoogle Scholar
  5. 5.
    American Diabetes Association (2017) Standards of medical care in diabetes—2017. Diabetes Care 40:S1–S138 (last accessed November 9, 2017) CrossRefGoogle Scholar
  6. 6.
    International Diabetes Federation (2012) Clinical guidelines task force. Global guideline for type 2 diabetes. Accessed 9 Nov 2017
  7. 7.
    AMD-SID (2016) Standard italiani per la cura del diabete mellito 2016. Accessed 9 Nov 2017 (Italian)
  8. 8.
    Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD (2012) Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev 1:CD005060PubMedGoogle Scholar
  9. 9.
    Parkin CG, Buskirk A, Hinnen DA, Axel-Schweitzer M (2012) Results that matter: structured vs. unstructured self-monitoring of blood glucose in type 2 diabetes. Diabetes Res Clin Pract 97:6–15CrossRefPubMedGoogle Scholar
  10. 10.
    International Diabetes Federation Clinical Guidelines Taskforce and International SMBG Working Group (2009) Global guideline on self-monitoring of blood glucose in noninsulin treated type 2 diabetes. Accessed 9 Nov 2017
  11. 11.
    Schnell O, Alawi H, Battelino T, Ceriello A (2009) Consensus statement on self-monitoring of blood glucose in diabetes: a European perspective. Diabetes Metab Heart 18:285–289Google Scholar
  12. 12.
    Franciosi M, Pellegrini F, De Berardis G et al (2001) The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients: an urgent need for better educational strategies. Diabetes Care 24:1870–1877CrossRefPubMedGoogle Scholar
  13. 13.
    Klonoff DC, Blonde L, Cembrowski G et al (2011) Consensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetes. J Diabetes Sci Technol 5:1529–1548CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rossi MC1, Candido R, Ceriello A et al (2015) Trends over 8 years in quality of diabetes care: results of the AMD Annals continuous quality improvement initiative. Acta Diabetol 52:557–571CrossRefPubMedGoogle Scholar
  15. 15.
    Schnell O, Alawi H, Battelino T et al (2011) Addressing schemes of self-monitoring of blood glucose in type 2 diabetes: a European perspective and expert recommendation. Diabetes Technol Ther 13:959–965CrossRefPubMedGoogle Scholar
  16. 16.
    Allemann S, Houriet C, Diem P, Stettler C (2009) Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis. Curr Med Res Opin 25:2903–2913CrossRefPubMedGoogle Scholar
  17. 17.
    Peel E, Parry O, Douglas M, Lawton J (2004) Blood glucose selfmonitoring in non-insulin-treated type 2 diabetes: a qualitative study of patients’ perspectives. Br J Gen Pract 54:183–188PubMedPubMedCentralGoogle Scholar
  18. 18.
    Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev BP (2007) Prediction of severe hypoglycemia. Diabetes Care 30:1370–1373CrossRefPubMedGoogle Scholar
  19. 19.
    Tavares R, Duclos M, Brabant MJ et al (2016) Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus. Acta Diabetol 53:483–492CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Farmer A, Balman E, Gadsby R et al (2008) Frequency of self-monitoring of blood glucose in patients with type 2 diabetes: association with hypoglycaemic events. Curr Med Res Opin 24:3097–3104CrossRefPubMedGoogle Scholar
  21. 21.
    Lecomte P, Romon I, Fosse S, Simon D, Fagot-Campagna A (2008) Self-monitoring of blood glucose in people with type 1 and type 2 diabetes living in France: the Entred study 2001. Diabetes Metab 34:219–226CrossRefPubMedGoogle Scholar
  22. 22.
    Metcalfe S, Moodie P, Norris H, Rasiah D (2014) Self-monitoring blood glucose test strip use with diabetes medicines in people with types 1 and 2 diabetes in New Zealand. N Z Med J 127:48–62PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  • Maria Chiara Rossi
    • 1
    Email author
  • Giuseppe Lucisano
    • 1
  • Antonio Ceriello
    • 2
    • 3
  • Chiara Mazzucchelli
    • 4
  • Nicoletta Musacchio
    • 5
  • Alessandro Ozzello
    • 6
  • Antonio Nicolucci
    • 1
  • Paolo Di Bartolo
    • 7
  • the AMD Annals-SMBG Study Group
  1. 1.CORESEARCH - Center for Outcomes Research and Clinical EpidemiologyPescaraItaly
  2. 2.Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomedica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)BarcelonaSpain
  3. 3.Department of Cardiovascular and Metabolic DiseasesIRCCS MultimedicaSesto San GiovanniItaly
  4. 4.IRCCS San MartinoGenoaItaly
  5. 5.AMDRomeItaly
  6. 6.Asl Torino 3PineroloItaly
  7. 7.AUSL RomagnaRavennaItaly

Personalised recommendations